{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"21","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Progression Free Survival is defined as the number of days from the day the subject started treatment to the day the subject experienced evidence of disease progression, as determined by radiological or clinical progression.","dispersionType":"Full Range","groups":[{"description":"Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.\n\nZometa: Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.","id":"OG000","title":"Zometa"}],"paramType":"MEDIAN","populationDescription":"Participants with advanced malignant pleural mesothelioma.","reportingStatus":"POSTED","timeFrame":"Baseline up to 28 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}